Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Motif Bio Plc (MTFB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9366
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Motif Bio Plc (Motif Bio), formerly Motif Bio Ltd, is a clinical-stage biopharmaceutical company that focuses on the development of novel antibiotics to treat patients with infections caused by multi-drug resistant bacteria. The company develops Iclaprim, a targeted Gram-positive1 antibiotic with activity against methicillin-resistant Staphylococcus aureus. Its indications for iclaprim include hospital-acquired bacterial pneumonia (HABP) including ventilator-associated bacterial pneumonia (VABP) and Staphylococcus aureus lung infections in people with cystic fibrosis. The company has operations in the UK and the US. Motif Bio is headquartered in London, the UK.

Motif Bio Plc (MTFB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Motif Bio Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Motif Bio Enters into Agreement with Covance 11
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 12
Merger 13
Motif Biosciences to Merge with Pharmaceutical Company 13
Equity Offering 14
Motif Bio Raises USD13.5 Million in Private Placement of Shares 14
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 15
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 16
Motif Bio Files Registration Statement to Raise up to USD80 Million in Public Offering of Securities 17
Motif Bio Files Registration Statement to Raise Funds through Private Placement of ADS upon Exercise of Warrants 18
Motif Bio to Raise USD0.1 Million in Public Offering of Shares up on Exercise of Warrants 19
Motif Bio to Raise USD25 million in Placing of New Ordinary Shares 20
Motif Bio Raises Funds through Private Placement of Shares and Warrants 21
Motif Bio Raises USD17 Million in Public Offering of American Depositary Shares and Warrants 23
Motif Bio Raises Funds through Private Placement upon Exercise of Warrants 25
Motif Bio Raises Funds in Private Placement upon Exercise of Warrants 26
Motif Bio Raises USD35 Million in Private Placement of Shares 27
Motif Bio Raises USD41.8 Million in IPO 28
Debt Offering 29
Motif Bio to Raise USD20 Million in Private Placement of Debt Financing 29
Acquisition 30
Motif BioSciences Acquires Nuprim 30
Motif Bio Plc – Key Competitors 31
Motif Bio Plc – Key Employees 32
Motif Bio Plc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Sep 25, 2018: Motif Bio announces Half-Year 2018 financial results and operational progress 34
Apr 10, 2018: Motif Bio Reports Fiscal Year 2017 Results 35
Sep 29, 2017: Motif Bio reports half-year 2017 financial results and operational progress 39
May 01, 2017: Motif Bio Reports Year-End 2016 Financial Results 40
May 01, 2017: Motif Bio annual net loss up 41
Corporate Communications 42
Jul 03, 2018: Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors 42
Feb 02, 2018: Motif Bio Appoints Jonathan E. Gold As Interim Chief Financial Officer 43
May 10, 2017: Motif Bio Appoints Scientific Opinion Leaders to Advisory Board 44
May 05, 2017: Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director 45
Jan 17, 2017: Motif Bio: Appointment of Chief Financial Officer 46
Government and Public Interest 47
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 47
Product News 48
06/22/2017: Motif Bio Invited to Present at Infectious Diseases Conference 48
Clinical Trials 49
Aug 09, 2017: Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase 49
Jul 06, 2017: Motif Bio to Present Three Posters at IDWeek 2017 50
May 01, 2017: Motif Bio Reports Year-end 2016 Financial Results 51
Apr 18, 2017: Motif Bio Announces Positive Results For Iclaprim, In The Revive-1 Phase 3 Study 52
Jan 30, 2017: Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase 53
Other Significant Developments 54
Mar 13, 2018: Motif Bio: Change of Registered Office 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Motif Bio Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Motif Bio Enters into Agreement with Covance 11
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 12
Motif Biosciences to Merge with Pharmaceutical Company 13
Motif Bio Raises USD13.5 Million in Private Placement of Shares 14
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 15
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 16
Motif Bio Files Registration Statement to Raise up to USD80 Million in Public Offering of Securities 17
Motif Bio Files Registration Statement to Raise Funds through Private Placement of ADS upon Exercise of Warrants 18
Motif Bio to Raise USD0.1 Million in Public Offering of Shares up on Exercise of Warrants 19
Motif Bio to Raise USD25 million in Placing of New Ordinary Shares 20
Motif Bio Raises Funds through Private Placement of Shares and Warrants 21
Motif Bio Raises USD17 Million in Public Offering of American Depositary Shares and Warrants 23
Motif Bio Raises Funds through Private Placement upon Exercise of Warrants 25
Motif Bio Raises Funds in Private Placement upon Exercise of Warrants 26
Motif Bio Raises USD35 Million in Private Placement of Shares 27
Motif Bio Raises USD41.8 Million in IPO 28
Motif Bio to Raise USD20 Million in Private Placement of Debt Financing 29
Motif BioSciences Acquires Nuprim 30
Motif Bio Plc, Key Competitors 31
Motif Bio Plc, Key Employees 32
Motif Bio Plc, Subsidiaries 33

List of Figures
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electricity Supply Board
    Electricity Supply Board - Strategy, SWOT and Corporate Finance Report Summary Electricity Supply Board - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • North Asia Strategic Holdings Limited:企業の戦略・SWOT・財務分析
    North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Midwest Energy Cooperative:企業の戦略的SWOT分析
    Midwest Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Tulane University:製薬・医療:M&Aディール及び事業提携情報
    Summary Tulane University (Tulane) is an educational service provider that provides biomedical courses and research programs. The university provides educational courses in the fields of architecture, business, law, liberal arts, medicine, public health and tropical medicine, science, engineering, a …
  • Schibsted ASA:企業のM&A・事業提携・投資動向
    Schibsted ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Schibsted ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Selexys Pharmaceuticals Corp-製薬・医療分野:企業M&A・提携分析
    Summary Selexys Pharmaceuticals Corp (Selexys Pharmaceuticals) is a biopharmaceutical company that develops drugs for the treatment of inflammatory and thrombotic diseases. The company’s products comprise Anti-P-selectin, which blocks selectin function and prevents white blood cells from initiating …
  • Chevron Corporation (CVX):石油・ガス:M&Aディール及び事業提携情報
    Summary Chevron Corp (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for, produces and transports crude oi …
  • The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd:企業の戦略的SWOT分析
    The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employee …
  • Credit Suisse (UK) Private Banking:企業の戦略・SWOT・財務情報
    Credit Suisse (UK) Private Banking - Strategy, SWOT and Corporate Finance Report Summary Credit Suisse (UK) Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Business Development Bank Of Canada:企業の戦略・SWOT・財務分析
    Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report Summary Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Terex Corp
    Terex Corp - Strategy, SWOT and Corporate Finance Report Summary Terex Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • PT Perusahaan Listrik Negara (Persero) Tbk:戦略・SWOT・企業財務分析
    PT Perusahaan Listrik Negara (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Perusahaan Listrik Negara (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Jyske Bank A/S:企業の戦略・SWOT・財務情報
    Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report Summary Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • VT Holdings Co Ltd (7593):企業の財務・戦略的SWOT分析
    VT Holdings Co Ltd (7593) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Canbriam Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Canbriam Energy Inc (Canbriam) is an oil and gas exploration company that offers finding and developing liquids rich natural gas resources. The company develops liquids rich natural gas resources in the Western Canadian Sedimentary Basin. It owns and operates oil and gas producing properties …
  • Ivy Cosmetics Corporation:企業の戦略・SWOT・財務分析
    Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report Summary Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Azul SA (AZUL4):企業の財務・戦略的SWOT分析
    Azul SA (AZUL4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • MicroStrategy Inc (MSTR):企業の財務・戦略的SWOT分析
    MicroStrategy Inc (MSTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • AB Sciex LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary AB Sciex LLC (Sciex), a subsidiary of Danaher Corp, is a provider of life science analytical technologies. The company provides mass spectrometry solutions combined with capillary electrophoresis and liquid chromatography. Its product portfolio includes liquid chromatography-mass spectromete …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆